

Investing in *transformative*  
life sciences companies.

## Strategy & Approach

Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. We invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over \$1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles.

Our venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile and attractive expected returns within three to five years from initial investment.

Longitude Capital seeks to identify new investment opportunities by tapping into our broad network of industry relationships

or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. We utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties and other equity and equity-linked instruments.

Following an initial investment, we work closely with our portfolio companies and syndicate partners to develop and implement strategic plans, achieve key operating objectives, build world class teams, raise capital and pursue liquidity opportunities in a manner that optimizes returns to key stakeholders.

Our company name was [inspired by the Longitude Prize](#), a competition established by the British monarchy in 1714 to solve one of the greatest scientific problems of the day.

## Our Team, Your Partners

Longitude Capital's founders have been investing together since 2002. Our team has over 150 years of combined investing experience in the life sciences industry and has collaborated on over 70 new investments and 150 follow-on investments in the biotechnology and medical technology sectors. We operate from our offices in Menlo Park, California and Greenwich, Connecticut.

---

### LEADERSHIP



**SANDIP**  
AGARWALA



**JULIET**  
BAKKER



**REINALDO**  
DIAZ



**PATRICK**  
ENRIGHT



MARC  
GALLETTI



GREGORY  
GRUNBERG



CAROLYN  
HELMS



DAVID  
HIRSCH



**JOSH**  
RICHARDSON

---

## **INVESTMENT PROFESSIONALS**



**DEREK**  
ABEL



**MAXWELL**  
BIKOFF





**CRISTINA**  
GHENOIU



**GARRETT**  
HOWARD



**OREN**  
ISACOFF



**ZANDER**  
LIEM



**BRIAN**  
LIU



**MICHAEL**  
WERT

---

## **OPERATIONS**



**TERESA**  
CABRERROS



**STEPHANIE**  
HOLMAN



NICOLE  
HUGHES



KAREN  
LOK



ALLISON  
LONDON



DINORAH  
MARTINEZ





SEINI  
MOIMOI



ERIN  
WRIGHT

## Investing in Healthcare Innovation

Longitude Capital invests in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system cost. From start-ups to growth equity investments, we are dedicated to helping management teams achieve technical, clinical and commercial milestones to create value and deliver attractive returns to our limited partners.

### PORTFOLIO

Current

Exited

— — — — —

— — — — —





— THERAPEUTICS



## News

Check out the latest news about Longitude Capital and our portfolio companies.

### PORTFOLIO NEWS

**2019**

**2018**

**2017**

**2016**

**2015**

**2014**

**2013**

*Jun 28*

Aimmune Submits Marketing Authorization Application to European Medicines for AR101 for Peanut...

*Jun 26*

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior...

*Jun 25*

Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of...

*Jun 24*

Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application...

*Jun 19*

Nabriva Therapeutics Submits Type A Meeting Request to FDA for Intravenous CONTEPO™...

*Jun 18*

Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI...

*Jun 17*

Neurana Pharmaceuticals Announces Completion of Enrollment in the Phase 2 Study of...

*Jun 17*

Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered...

*Jun 11*

Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with...

*Jun 04*

Data from Two Studies Confirm Quality of Life and Psychosocial Burden of...

OLDER

---

## LONGITUDE CAPITAL NEWS

*02.16.17*

Longitude Capital Promotes Josh Richardson, M.D. To Managing Director

*06.07.16*

Longitude Capital Closes \$525 Million Fund

*05.20.15*

Longitude Capital Promotes Sandip K. Agarwala To Managing Director

*03.17.14*

Longitude Capital Maintains Momentum with Promotions and Team Expansion

*10.11.12*

Longitude Capital pumps \$385M into new life sciences fund

*10.10.12*

Longitude Capital Closes Second Life Sciences Fund with \$385 Million in Commitments

*10.10.12*



Longitude Capital Beats Target for Fund II, Raises \$385M for Biotech, Medtech...

*02.08.12*

Longitude Capital Expands Investment Team With Senior Hire

## Contact Us

### **MENLO PARK, CALIFORNIA**

2740 Sand Hill Road, 2nd Floor  
Menlo Park, CA 94025  
650.854.5700

[Click here for directions](#)

### **GREENWICH, CONNECTICUT**

One Fawcett Place  
Greenwich, CT 06830  
203.769.5200

[Click here for directions](#)

COMMENT

SUBMIT



CAPITAL

LP LOGIN

© 2016 Longitude Capital. All rights reserved. [Privacy Policy](#) [Disclaimer](#)